Allogeneic CAR-T therapy gets go-ahead for rheumatology trial
Allogene Therapeutics has been given the green light from the US Food and Drug Administration (FDA) for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR-T product.
The Phase I RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.
The trial design leverages Dagger technology to drive CAR T cell expansion and prevent rejection. It includes two distinct lymphodepletion arms: one using a dose of cyclophosphamide alone which is used by rheumatologists, and another that eliminates lymphodepletion entirely.
“A year ago, we unveiled the concept of ALLO-329, an allogeneic CAR-T product specifically designed to address the unique challenges faced by patients with autoimmune diseases. Today, with the FDA’s clearance of our IND, that vision has become a reality,” said David Chang, President, CEO, and Co-Founder of Allogene.
“Demonstrating the power of an allogeneic CAR T to reset the immune system, combined with the ability of our Dagger technology to reduce or eliminate lymphodepletion, could represent a transformative step forward. Successful proof-of-concept in this basket study has the potential to not only validate our best-in-class approach but also paves the way for expanding into a broad range of autoimmune indications beyond rheumatology.”
ALLO-329 features a dual-targeting design against CD19+ B-cells and CD70+ activated T-cells. This strategy is designed to deliver superior therapeutic benefit by addressing both B-cell and T-cell dysfunction, which drive immune dysregulation in autoimmune diseases.
If successful, this CAR-T advancement could meet the potential scale required to treat autoimmune disease, with the capacity to manufacture upwards of 60,000 doses per year, and expand access to CAR-T therapy across a wide range of autoimmune disease indications.
Diana Spencer, Senior Digital Content Editor, DDW
